Literature DB >> 31848494

[Significance of anti-carbamylated protein antibodies in patients with rheumatoid arthritis-associated intersitial lung disease].

H Zhu1, L J Zhao2, Y Zhou1, Y Chen2.   

Abstract

OBJECTIVE: To evaluate the value of anti-carbamylated protein (CarP) antibody in the diagnosis of rheumatoid arthritis-associated intersitial lung diseas (RA-ILD).
METHODS: Clinical and laboratory data and serum samples of patients with RA between December 2017 and June 2019 in Department of Rheumatology, General Hospital of Ningxia Medical University were collected. The patients were subclassified as RA-ILD and RA-without ILD based on computed tomography scans of the chest, Enzyme 1inked immunosorbent assay (ELISA) was used to assess anti-CarP antibody in the serum of each group. The occurrence of ILD and other laboratory indexes were analyzed. Comparison of measurement data between the 2 groups was performed by two independent sample t-test or Mann-Whitney U nonparametric test, while the count data were compared by Chi square test; Receiver operating characteristic curve (ROC) was drawn to determine the cut-off value of anti-CarP antibody to RA-ILD diagnosis and to analyze its diagnostic efficacy.
RESULTS: The anti-CarP antibody level in the RA-ILD group was 21.14 (12.29, 29.75), which was significantly higher than that in the RA-without ILD group 11.6 (6.66, 19.05) (P=0.000). The difference was statistically significant (P<0.05). The positive rate of anti-CarP antibody in RA-ILD group (53%) was significantly higher than that in RA-without ILD group (16%) (P<0.05); There was no significant differences in the levels of rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) between the two groups (P>0.05). The age and disease activity score (DAS28) in the RA-ILD group were significantly higher than those in the RA-withhout ILD group (P<0.05). The proportion of men and smoking in the RA-ILD group was higher than that in the RA-without ILD group, but the difference was not statistically significant. The ROC curve showed that the anti-CarP antibody had a cut off value of 20.56 U/mL, with the sensitivity of 53.50%, and specificity of 84.20%, the area under the ROC curve were 0.76. Spearman correlation analysis showed that rheumatoid factor (RF) and age were positively correlated with anti-CarP antibody (r=0.172, P=0.043; r=0.200, P=0.006). Anti-CarP antibody level was not associated with the DAS28 score, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), anti-CCP antibody, swollen joint count, and tender joint count (P>0.05).
CONCLUSION: The anti-CarP antibody level in RA-ILD patients is higher than that in RA-without ILD, suggesting that anti-CarP antibody may have a role in the development of RA-ILD.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31848494      PMCID: PMC7433599     

Source DB:  PubMed          Journal:  Beijing Da Xue Xue Bao Yi Xue Ban        ISSN: 1671-167X


  17 in total

1.  Autoantibodies recognizing carbamylated proteins are present in sera of patients with rheumatoid arthritis and predict joint damage.

Authors:  Jing Shi; Rachel Knevel; Parawee Suwannalai; Michael P van der Linden; George M C Janssen; Peter A van Veelen; Nivine E W Levarht; Annette H M van der Helm-van Mil; Anthony Cerami; Tom W J Huizinga; Rene E M Toes; Leendert A Trouw
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-10       Impact factor: 11.205

2.  [Diagnostic value of anti-cyclic citrullinated peptide antibody for rheumatoid arthritis: a meta-analysis].

Authors:  Qing-shui Huang; La-gen Wan; Zhong-qin Luo; Ai-ping Le; Wen-qiang Wang
Journal:  Zhonghua Yi Xue Za Zhi       Date:  2006-08-22

3.  Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests.

Authors:  J K Dawson; H E Fewins; J Desmond; M P Lynch; D R Graham
Journal:  Thorax       Date:  2001-08       Impact factor: 9.139

4.  Anti-carbamylated protein antibodies are present in arthralgia patients and predict the development of rheumatoid arthritis.

Authors:  Jing Shi; Lotte A van de Stadt; E W Nivine Levarht; Tom W J Huizinga; René E M Toes; Leendert A Trouw; Dirkjan van Schaardenburg
Journal:  Arthritis Rheum       Date:  2013-04

5.  Clinical and high resolution computed tomography characteristics of patients with rheumatoid arthritis lung disease.

Authors:  Nadiah Mohd Noor; Mohamed Said Mohd Shahrir; Mohd Shahdan Shahid; Roslina Abdul Manap; Ahmad Mukari Shahizon Azura; Shamsul Azhar Shah
Journal:  Int J Rheum Dis       Date:  2009-07       Impact factor: 2.454

6.  The clinical significance of HRCT in evaluation of patients with rheumatoid arthritis-associated interstitial lung disease: a report from China.

Authors:  Yu-Qiong Zou; Ya-Song Li; Xiao-Nan Ding; Zhen-Hua Ying
Journal:  Rheumatol Int       Date:  2010-12-05       Impact factor: 2.631

Review 7.  Carbamylated LDL.

Authors:  Alexei G Basnakian; Sudhir V Shah; Ercan Ok; Ekrem Altunel; Eugene O Apostolov
Journal:  Adv Clin Chem       Date:  2010       Impact factor: 5.394

8.  The lung may play a role in the pathogenesis of rheumatoid arthritis.

Authors:  M Kristen Demoruelle; Joshua J Solomon; Aryeh Fischer; Kevin D Deane
Journal:  Int J Clin Rheumtol       Date:  2014

9.  Clinical and laboratory factors associated with interstitial lung disease in rheumatoid arthritis.

Authors:  José Félix Restrepo; Inmaculada del Rincón; Daniel F Battafarano; Roy W Haas; Merced Doria; Agustín Escalante
Journal:  Clin Rheumatol       Date:  2015-08-09       Impact factor: 2.980

10.  Meta-Analysis: Diagnostic Accuracy of Anti-Carbamylated Protein Antibody for Rheumatoid Arthritis.

Authors:  Liubing Li; Chuiwen Deng; Si Chen; Shulan Zhang; Ziyan Wu; Chaojun Hu; Fengchun Zhang; Yongzhe Li
Journal:  PLoS One       Date:  2016-07-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.